| Today’s Big NewsMar 3, 2025 |
|
Tuesday, March 11, 2025 | 11am ET / 8am PT In the world of clinical trials, where precision and compliance are critical, the role of technology is more important than ever. Join us to learn how to harness the latest innovations for driving efficiencies and more streamlined experiences for patients. Register now to take a deep dive into the most pressing challenges in clinical trials today!
|
|
| By Gabrielle Masson After a rocky two years, money has started flowing back to biotech, with the return of the megaround exemplified in top moneymaker Xaira’s $1 billion fundraise. |
|
|
|
By Kevin Dunleavy Over nearly the last three decades, Genentech has had the lone medicine on the market for stroke. On Monday, the Roche subsidiary added a second stroke treatment to its repertoire, gaining an FDA endorsement for TNKase. |
By Conor Hale The acquisition sets up the company to potentially compete against Medtronic and Recor Medical—whose respective FDA-approved procedures received temporary reimbursements from Medicare at the top of this year. |
By Nick Paul Taylor AbbVie is paying $350 million to join the obesity race. The outlay, plus up to $1.875 billion in milestones, has landed the drugmaker rights to a long-acting amylin analog that is in phase 1 development at Gubra. |
By Angus Liu Already billed as a potential blockbuster, Amgen and AstraZeneca’s Tezspire has turned in strong clinical data in chronic rhinosinusitis with nasal polyps (CRSwNP). In reviewing the data drop, William Blair analysts said the results “hint at best-in-disease therapy.” |
By Fraiser Kansteiner Beginning in late May, BMS will lay off 223 workers in Lawrenceville, New Jersey, where the company hosts its corporate headquarters, as well as a facility for commercial and late-stage development work. The downsizing initiative is part of BMS’ broader effort to cut costs. |
By Kevin Dunleavy A year after the FDA blessed Roche and Novartis’ Xolair (omalizumab) as the first medicine to reduce allergic reactions that can occur from accidental exposure to certain foods, the companies have presented data indicating Xolair may be more effective than oral immunotherapy (OIT) in treating food allergies. |
By Gabrielle Masson Pliant Therapeutics has discontinued a phase 2b/3 trial after recording at least a 7% higher rate of adverse events tied to idiopathic pulmonary fibrosis (IPF) in the treatment arms compared to placebo. |
By Conor Hale The KidneyVault is more than a simple ice chest. It pumps a cooled, specialized solution through the organ to help preserve it on the way to surgery. |
By James Waldron Takeda’s $300 million bet on Protagonist Therapeutics’ hematology asset a year ago appears to have paid off as the drug reduced blood procedures among patients with a rare type of cancer in a phase 3 trial. |
Fierce podcastsDon’t miss an episode |
| | This week on "The Top Line," we hear from Steven McCarroll, Ph.D., whose research team at the Broad Institute of MIT and Harvard recently uncovered new insights into the cause of Huntington's disease. |
|
|---|
|
|
|
Wednesday, April 9, 2025 | 10am ET / 7am PTLearn the key steps for successfully entering Japan’s pharmaceutical market. This webinar covers regulatory requirements, compliance strategies, supply chain best practices, and common challenges. Gain expert insights to navigate this high-potential market with confidence. Don’t miss out—register now to secure your spot!
|
|
| WhitepaperRead about four trends that will shape the innovations, therapies, & market landscape in oncology during 2025 & beyond. Presented by Blue Matter, strategic consultants in the life sciences |
| WhitepaperDiscover how to revolutionize your vaccine trials with Avacare's latest white paper. Gain exclusive access to innovative, data-driven recruitment strategies that ensure diverse, efficient, and high-quality vaccine trials. Sponsored by: Avacare Clinical Research Network |
| WhitepaperDevelop your CAR molecule faster Sponsored by: Cell Signaling Technology |
| |
|
